Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för umbralisib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

7 träffar

Bibliografisk träff 2023-08-22

Discovery of Highly Selective and Orally Bioavailable PI3Kδ Inhibitors with Anti-Inflammatory Activity for Treatment of Acute Lung Injury.

Tang Y, Zheng F, Bao X, Zheng Y, Hu X, Lou S, Zhao H, Cui S.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.3c00508

Bibliografisk träff 2022-11-28

Recent advances in PI3K/PKB/mTOR inhibitors as new anticancer agents.

Occhiuzzi MA, Lico G, Ioele G, De Luca M, Garofalo A, Grande F.

Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2022.114971

Bibliografisk träff 2021-05-27

Focused Libraries for Epigenetic Drug Discovery: The Importance of Isosteres.

Green AI, Burslem GM.

J Med Chem · journal article · DOI 10.1021/acs.jmedchem.1c00592

Bibliografisk träff 2020-11-12

Discovery of (S)-2-(1-(4-Amino-3-(3-fluoro-4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propyl)-3-cyclopropyl-5-fluoroquinazolin-4(3H)-one (IHMT-PI3Kδ-372) as a Potent and Selective PI3Kδ Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease.

Li F, Liang X, Jiang Z, Wang A, Wang J, Chen C, Wang W, Zou F, Qi Z, Liu Q, Hu Z, Cao J, Wu H, Wang B, Wang L, Liu J, Liu Q.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.0c01544

Bibliografisk träff 2018-12-24

Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune Diseases.

Perry MWD, Abdulai R, Mogemark M, Petersen J, Thomas MJ, Valastro B, Westin Eriksson A.

J Med Chem · review; journal article · DOI 10.1021/acs.jmedchem.8b01298

Bibliografisk träff 2018-12-04

Targeting the immunity protein kinases for immuno-oncology.

Yuan X, Wu H, Bu H, Zhou J, Zhang H.

Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2018.11.072

Bibliografisk träff 2016-10-26

Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies.

Deng C, Lipstein MR, Scotto L, Jirau Serrano XO, Mangone MA, Li S, Vendome J, Hao Y, Xu X, Deng SX, Realubit RB, Tatonetti NP, Karan C, Lentzsch S, Fruman DA, Honig B, Landry DW, O'Connor OA.

Blood · research-article; journal article · DOI 10.1182/blood-2016-08-731240

Gå till forskningen.

Publikationer i urvalet

Discovery of Highly Selective and Orally Bioavailable PI3Kδ Inhibitors with Anti-Inflammatory Activity for Treatment of Acute Lung Injury.

Recent advances in PI3K/PKB/mTOR inhibitors as new anticancer agents.

Focused Libraries for Epigenetic Drug Discovery: The Importance of Isosteres.

Discovery of (<i>S</i>)-2-(1-(4-Amino-3-(3-fluoro-4-methoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)propyl)-3-cyclopropyl-5-fluoroquinazolin-4(3<i>H</i>)-one (IHMT-PI3Kδ-372) as a Potent and Selective PI3Kδ Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease.

Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune Diseases.

Targeting the immunity protein kinases for immuno-oncology.

Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies.